In a breakthrough study, scientists at Johns Hopkins have mapped out a key chemical step involved in blocking enzyme action in heart failure.
In a breakthrough study, scientists at Johns Hopkins have mapped out a key chemical step involved in blocking enzyme action in heart failure.
The team showed how the enzyme, phosphodiesterase 5, or PDE5A, involved in heart failure, slows down the breakdown of another vital compound called, cyclic guanosine monophosphate (cyclic GMP), which is critical to cell growth and muscle contraction.
This so-called S-nitrosylation of amino acid cysteine 181 lead to a 25 percent reduction in PDE5A activity, pinpointing how the enzyme's action is suppressed.
"Knowing the molecular make-up and activity of a protein is critical to understanding heart failure because these problem-specific biochemical reactions are magnified in the disease," said senior study investigator Jennifer Van Eyk, Ph.D., a professor at the Johns Hopkins University School of Medicine and its Heart and Vascular Institute.
Small Doses of Toxic Gases Protects Mice from Heart Failure
Despite its rotten-egg smell and high toxicity, hydrogen sulfide in small doses helps protect mice from heart failure, according to research published Tuesday on an experimental treatment
Despite its rotten-egg smell and high toxicity, hydrogen sulfide in small doses helps protect mice from heart failure, according to research published Tuesday on an experimental treatment
The researchers said that their next step is to investigate how PDE5A affects where cyclic GMP is broken down or made, with the goal of determining if the enzyme also controls the known cell pooling of the compound.
Advertisement
Clinical Trial Shows Promising Results of Gene Therapy for Heart Failure
American scientists behind the phase I clinical trial of gene therapy for heart failure patients.
American scientists behind the phase I clinical trial of gene therapy for heart failure patients.
Source-ANI
SRM
